CSPC Innovation Pharmaceutical's (SHE:300765) drug, SYS6010, was included in the Breakthrough Therapy Product List of China's National Medical Products Administration, according to a Shenzhen bourse filing on Tuesday.
The Chinese pharmaceutical company's shares rose 2% during Wednesday's morning trade.
The drug, which was developed by subsidiary Shijiazhuang CSPC Jushi Biopharmaceutical, is used for the treatment of patients with relapsed or metastatic head and neck squamous cell carcinoma who have failed to respond to immunotherapy and platinum-containing chemotherapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments